• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Efficacy of escitalopram oxalate for patients with post-stroke depression.草酸艾司西酞普兰对脑卒中后抑郁患者的疗效。
Medicine (Baltimore). 2018 Apr;97(14):e0219. doi: 10.1097/MD.0000000000010219.
2
Depressive Symptoms in Stroke Patients: Are There Sex Differences?中风患者的抑郁症状：存在性别差异吗？
Cerebrovasc Dis. 2020;49(1):19-25. doi: 10.1159/000506116. Epub 2020 Feb 5.
3
A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.艾司西酞普兰与帕罗西汀对重度抑郁症患者长期治疗效果的比较研究。
Curr Med Res Opin. 2006 Jul;22(7):1331-41. doi: 10.1185/030079906X115513.
4
Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.米氮平与西酞普兰的疗效及耐受性：一项针对重度抑郁症患者的双盲、随机研究。北欧抗抑郁药研究小组
Int Clin Psychopharmacol. 1999 Nov;14(6):329-37. doi: 10.1097/00004850-199911000-00002.
5
Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model.艾司西酞普兰（西酞普兰的S-对映体）：基于大鼠模型预测的临床疗效及起效时间
Pharmacol Toxicol. 2001 May;88(5):282-6. doi: 10.1034/j.1600-0773.2001.d01-118.x.
6
Efficacy of escitalopram in patients with severe depression: a pooled analysis.艾司西酞普兰治疗重度抑郁症患者的疗效：一项汇总分析。
Int J Clin Pract. 2005 Mar;59(3):268-75. doi: 10.1111/j.1742-1241.2005.00440.x.
7
Escitalopram in the treatment of anxiety symptoms associated with depression.艾司西酞普兰治疗与抑郁症相关的焦虑症状。
Depress Anxiety. 2007;24(1):53-61. doi: 10.1002/da.20141.
8
Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.依西酞普兰对心力衰竭合并抑郁患者全因死亡率和住院率的影响：MOOD-HF 随机临床试验。
JAMA. 2016 Jun 28;315(24):2683-93. doi: 10.1001/jama.2016.7635.
9
The onset of effect for escitalopram and its relevance for the clinical management of depression.艾司西酞普兰的起效时间及其与抑郁症临床管理的相关性。
Curr Med Res Opin. 2006 Nov;22(11):2101-10. doi: 10.1185/030079906X148319.
10
Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.艾司西酞普兰与度洛西汀治疗重度抑郁症急性期的双盲对照研究
Clin Drug Investig. 2007;27(7):481-92. doi: 10.2165/00044011-200727070-00005.

引用本文的文献

1
Serotonin Selective Reuptake Inhibitors (SSRIs) and Stroke.选择性 5-羟色胺再摄取抑制剂（SSRIs）与卒中。
Curr Neurol Neurosci Rep. 2018 Oct 23;18(12):100. doi: 10.1007/s11910-018-0904-9.

本文引用的文献

1
Distribution of symptoms of post-stroke depression in relation to some characteristics of the vulnerable patients in socio-cultural context.社会文化背景下，中风后抑郁症症状分布与易患患者某些特征的关系。
Afr Health Sci. 2017 Mar;17(1):70-78. doi: 10.4314/ahs.v17i1.10.
2
Post-Stroke Depression: Impact of Lesion Location and Methodological Limitations-A Topical Review.中风后抑郁症：病变部位的影响及方法学局限性——专题综述
Front Neurol. 2017 Sep 21;8:498. doi: 10.3389/fneur.2017.00498. eCollection 2017.
3
A risk prediction model for post-stroke depression in Chinese stroke survivors based on clinical and socio-psychological features.基于临床和社会心理特征的中国卒中幸存者卒中后抑郁风险预测模型
Oncotarget. 2017 Apr 7;8(38):62891-62899. doi: 10.18632/oncotarget.16907. eCollection 2017 Sep 8.
4
Post-stroke depression: different characteristics based on follow-up stage and gender-a cohort perspective study from Mainland China.中风后抑郁：基于随访阶段和性别的不同特征——来自中国大陆的队列研究
Neurol Res. 2017 Nov;39(11):996-1005. doi: 10.1080/01616412.2017.1364514. Epub 2017 Aug 22.
5
Risk Factors for Post-stroke Depression: A Meta-analysis.中风后抑郁的危险因素：一项荟萃分析。
Front Aging Neurosci. 2017 Jul 11;9:218. doi: 10.3389/fnagi.2017.00218. eCollection 2017.
6
Nonpharmacological Treatments for Post-Stroke Depression: An Integrative Review of the Literature.中风后抑郁症的非药物治疗：文献综合综述
Res Gerontol Nurs. 2017 Jul 1;10(4):182-195. doi: 10.3928/19404921-20170524-02. Epub 2017 May 30.
7
Interventions for treating anxiety after stroke.中风后焦虑症的治疗干预措施。
Cochrane Database Syst Rev. 2017 May 23;5(5):CD008860. doi: 10.1002/14651858.CD008860.pub3.
8
Cerebellar Fastigial Nucleus Electrical Stimulation Alleviates Depressive-Like Behaviors in Post-Stroke Depression Rat Model and Potential Mechanisms.小脑顶核电刺激减轻脑卒中后抑郁大鼠模型的抑郁样行为及潜在机制
Cell Physiol Biochem. 2017;41(4):1403-1412. doi: 10.1159/000467940. Epub 2017 Mar 16.
9
Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population.艾司西酞普兰治疗伴有焦虑症状的重度抑郁症的疗效和耐受性：一项针对中国人群的24周开放标签前瞻性研究。
Neuropsychiatr Dis Treat. 2017 Feb 17;13:515-526. doi: 10.2147/NDT.S120190. eCollection 2017.
10
Behavioural Activation Therapy for Depression after Stroke (BEADS): a study protocol for a feasibility randomised controlled pilot trial of a psychological intervention for post-stroke depression.中风后抑郁症的行为激活疗法（BEADS）：一项针对中风后抑郁症心理干预可行性随机对照试验的研究方案。
Pilot Feasibility Stud. 2016 Aug 10;2:45. doi: 10.1186/s40814-016-0072-0. eCollection 2016.

草酸艾司西酞普兰对脑卒中后抑郁患者的疗效。

Efficacy of escitalopram oxalate for patients with post-stroke depression.

作者信息

Xu Ji-Hua, Jiang Peng

机构信息

Department of Neurolgy, Beijing ChaoYang Hospital, Capital Medical University, Beijing, China.

出版信息

Medicine (Baltimore). 2018 Apr;97(14):e0219. doi: 10.1097/MD.0000000000010219.

DOI:10.1097/MD.0000000000010219
PMID:29620632
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5902280/
Abstract

This retrospective study investigated the efficacy and safety of escitalopram oxalate (ESO) for the treatment of post-stroke depression (PSD).A total of 115 patients with PSD were included in this study. A total of 65 patients underwent ESO (Intervention group). A total of 50 patients received acupressure (Control group). The outcome measurements included Montgomery-Åsberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM-A), and Sheehan Disability Scale (SDS). In addition, we also recorded the adverse events in this study.At the end of 8-week treatment, ESO showed greater efficacy in depression, measured by MADRS (P < .01); anxiety, measured by HAM-A scale (P < .01); and disability, measured by SDS (P < .01), compared to acupressure. Additionally, there were not significant differences regarding adverse events between two groups (P > .05).The present results indicate that ESO can decrease symptoms of patients with PSD.

摘要

这项回顾性研究调查了草酸艾司西酞普兰（ESO）治疗卒中后抑郁（PSD）的疗效和安全性。本研究共纳入115例PSD患者。其中65例患者接受ESO治疗（干预组）。另外50例患者接受指压治疗（对照组）。疗效指标包括蒙哥马利-艾斯伯格抑郁量表（MADRS）、汉密尔顿焦虑量表（HAM-A）和希恩残疾量表（SDS）。此外，我们还记录了本研究中的不良事件。在8周治疗结束时，与指压治疗相比，ESO在通过MADRS评估的抑郁（P<0.01）、通过HAM-A量表评估的焦虑（P<0.01）以及通过SDS评估的残疾方面（P<0.01）均显示出更高的疗效。此外，两组之间在不良事件方面无显著差异（P>0.05）。目前的结果表明，ESO可减轻PSD患者的症状。